Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...

From 1,085 citations identified, 48 studies with 15,368 men with mCRPC met inclusion criteria. Most studies were retrospective cohorts (n = 39) from Europe (n = 22) and North America (n = 18), with ...

SAN FRANCISCO -- Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when ...

Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS ...

The American Cancer Society's chief scientific officer outlines the group's research agenda, including a new project in ...

Alerts delivered via the electronic health record temporarily reduces unnecessary screening and treatment but does not create ...

The 63-year-old musician revealed his stage 4 prostate cancer diagnosis in November 2022, saying his cancer was “asymptomatic ...

A nurse-led mobile healthcare clinic identified a high proportion of clinically significant prostate cancers among men from ...

Having raised more than $1 million toward cancer research over the past nine years, the tournament is on the road to raising ...

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...